Do I Have to Stop My Blood Thinner Before an Eye Injection?
What to Do About Your Blood Thinner Right Now
Start here, before anything else. Anticoagulants should not be discontinued without consultation with the provider managing them1. Skipping doses on your own is the clearest risk here. Do not do it. Call 911 for weakness on one side, facial droop, trouble speaking, chest pain, or sudden severe headache. Call your eye doctor the same day if, after an injection, you notice any of these:
- Eye pain or discomfort that is building rather than settling.
- Decreased vision in the treated eye.
- Redness that is getting worse instead of fading.
- New or increased floaters after the first day.
- New light sensitivity.
The American Academy of Ophthalmology tells injection clinics to warn patients about these signs. Pain, worsening redness, reduced vision, new light sensitivity, or more floaters can mean an infection inside the eye2. Most people get none of them. The list is here so the rare case is seen in hours, not days. That is when care works best.
Most people keep taking their blood thinner. An eye injection uses a very fine needle into a part of the eye that bleeds very little. Across 3,106 anti-VEGF injections in 520 patients, including 548 injections in people taking warfarin and 523 in people taking clopidogrel, no hemorrhagic complications were recorded in the warfarin, clopidogrel or aspirin groups, and the authors recommended continuing the current regimen without stopping it, citing the thromboembolic risk of stopping3. Larger recent data are less uniformly reassuring, and the section below sets the two side by side. That is the usual answer, not a rule for you personally.
Your blood thinner exists to hold off a clot somewhere else in your body, and the person who knows that risk best is not the person holding the needle. The operating eye surgeon should not be the one to tell a patient whether to withdraw an antithrombotic medicine or for how long, because the prescribing physician, whether internist, cardiologist or neurologist, knows the risk profile much better and is the appropriate person to make that call4. So the real answer to your question usually comes from a short phone call between two clinics, not from a web page.
Blood Thinners and Eye Injections at a Glance
An eye injection is not a needle across the front of your eye. An intravitreal injection places medicine directly into the vitreous cavity, the jelly-filled space at the back of the eye, and it is used for age-related macular degeneration, diabetic retinopathy and retinal vein occlusion. The eye is numbed with drops or gel, cleaned with povidone-iodine, held open with a small lid holder, and the medicine goes in through the pars plana, the white part of the eye, with a very small needle. The whole visit takes about 10 to 15 minutes, and people usually feel pressure with little or no pain5.
The worry is reasonable, and it splits into two very different sizes of problem. The common one is a red patch on the white of the eye where the needle went in, which looks dramatic and is harmless. The rare one is bleeding inside the eye, which can affect sight. A small bleed on the surface of the eye where the needle enters usually heals within a week5. Blood thinners make the first kind more likely and more colorful. The question everyone actually cares about is whether they change the second kind.
Blood thinner is an everyday word covering two different drug families. Anticoagulants, such as warfarin and the newer direct oral anticoagulants, slow the chemical clotting cascade. Antiplatelets, such as aspirin and clopidogrel, stop platelets sticking together. Doctors group them as antithrombotics. The distinction matters here because the evidence treats them separately, and because your team may take a different view of a daily aspirin than of a drug protecting a mechanical heart valve.
How the Injection Is Done, and Why That Keeps Bleeding Small
The preparation is most of the appointment. The Academy's clinical statement describes anesthetics, povidone-iodine applied to the eye surface, and drops to widen the pupil as part of the procedure, and notes that routine antibiotics are not indicated2. The iodine step is the one that stings and the one that matters most, because it is aimed at the infection risk rather than the bleeding risk.
The needle enters through the white of the eye a few millimeters behind the edge of the colored part, at a spot chosen to avoid the lens and the retina. It is over in seconds. Patients feel pressure with little or no pain during the injection, and a temporary rise in eye pressure usually returns to normal within a few minutes5. Nobody stitches anything afterwards, because the opening is too small to need it.
The needle crosses the white coat of the eye, a tough layer with only a thin film of small surface vessels over it. Nicking one of those surface vessels produces the red patch people notice. The vessels that could cause sight-threatening bleeding sit deeper, in the retina and the layer beneath it, and the needle path is planned to stay clear of them. That anatomy, more than any drug decision, is why serious bleeding after an injection is uncommon.
What the Evidence Says About Injecting While on a Blood Thinner
One retrospective series is quoted more than any other on this question, and it is worth knowing what it did and did not cover. It followed 520 consecutive patients through 3,106 anti-VEGF injections, split into a warfarin group of 104 patients, a clopidogrel group of 90 patients, 7 patients taking both, and 1,254 injections given to people on aspirin, and it recorded no choroidal hemorrhage, vitreous hemorrhage or worsening bleeding under the macula in any of those groups3. It was a single center, and it could not rule out a small effect it was too small to see.
A much bigger and more recent analysis found a signal, and honesty means putting it next to the first one. In a nationwide study of 94,449 people with wet age-related macular degeneration, with a nested comparison of 8,110 patients, the odds of bleeding inside the eye severe enough to need vitrectomy surgery were about 1.9 times higher with anticoagulants, about 1.4 times higher with antiplatelets and about 2.3 times higher when both were taken together6. Those are relative figures. They describe how much more likely the event was, not how often it happened, and needing surgery for a bleed remains an uncommon outcome.
They are answering slightly different questions, and both can be right. The first asked whether the injection itself causes bleeding in people on these drugs. The second asked whether people on these drugs, who also have a bleeding-prone eye disease, end up needing surgery for a bleed more often over years. The authors of the larger study did not call for stopping the medicines. They called for proactive communication and tailored monitoring6. That is the practical takeaway: the finding changes what your team watches for, not usually what you swallow each morning.
Who Continues, Who Might Be Asked to Pause, and Who Should Not Stop
For a routine eye injection, the common path is that nothing about your medicines changes. Your eye doctor records what you take, notes it on the chart, and proceeds. Expect to be told your eye may look redder than usual afterwards. Ask for that expectation in plain words before the first injection, so a red eye in the bathroom mirror is a fact you were warned about rather than a fright at midnight.
Pausing comes up more with eye surgery than with injections, and the size of the operation drives it. Peri-procedural guidance grades eye procedures by bleeding risk, with cataract surgery treated as very low risk (no hold for aspirin, and anything from no hold to a 3-day hold for warfarin), retinal and glaucoma operations treated as intermediate risk, and operations such as orbital decompression or lower lid surgery treated as high risk, with holds of about 5 days for warfarin and 7 to 10 days for aspirin and clopidogrel1. Those windows are for operations, not for a routine injection, and they are set by the prescriber rather than by the surgeon. If someone quotes you a hold, ask which procedure the number belongs to.
Some reasons for taking a blood thinner make an unsupervised pause the riskiest thing in the room. In people with atrial fibrillation or a mechanical heart valve, about 20 of every 100 thromboembolic episodes are fatal and about 40 of every 100 cause permanent disability, and clotting after antiplatelet therapy is stopped early in people with a stent is fatal in up to about 40 of every 100 cases4. Read that as a reason to make one phone call, not a reason to panic. If you have a mechanical valve, a recent stent, a recent clot in the leg or lung, or an irregular heartbeat, say so early and let the prescriber decide.
What to Settle at the Consultation
Bring a current medicine list rather than a memory of it, including anything bought over the counter. Aspirin and fish oil often get left off because people do not count them as medicines. Say who prescribes each blood thinner and why, since the reason drives the decision far more than the drug name does. If you have had a bleed inside the eye before, or a bleeding disorder, mention it without waiting to be asked.
Ask three things and write the answers down. Does anything about my medicines change for this injection, and who decided that? What will my eye look like afterwards, and for how long? Who do I call out of hours if something looks wrong? There are not yet clear guidelines on how to manage the newer oral anticoagulants in patients needing eye operations, and clinicians are advised to assess each patient's bleeding risk individually7. Different clinics landing on slightly different answers is a sign of that gap, not of carelessness.
After the Injection: What Is Normal and What Is Not
Expect grittiness and mild soreness for a day or so, from the iodine and the lid holder more than the needle. Vision is often blurry for a few hours. Floaters can appear and usually settle. Plan not to drive yourself home after the first injection until you know how you react. The plan is different if something on the warning list appears, in which case the appointment you want is today rather than at your next scheduled visit.
This is the part blood thinners genuinely change, and it is the part that matters least. A bright red patch on the white of the eye is blood trapped under the clear surface membrane, not inside the eye. It looks worse over the first two days as it spreads, then fades through green and yellow. A small bleed where the needle enters usually clears within a week5. It does not blur vision or hurt. If it does either of those things, it is not this.
Numbers are steadier than adjectives here. In a review drawing on a series of 45,000 eyes, the total complication rate was under 2 of every 100 injections, and about 74 of every 100 of those complications were minor and needed no treatment, such as a surface bleed or irritation; infection inside the eye ranged from about 1 of every 10,000 injections to about 3 of every 1,000, and retinal detachment directly from an injection ranged from none up to about 7 of every 1,0008. Those rates are for injections in general, not for people on blood thinners specifically. Set against them is the reason the injections were recommended in the first place.
When to Call Your Eye Doctor and When to Call 911
Report eye pain or discomfort, increased floaters after the first day, increased sensitivity to light, and decreased vision straight away5. Add worsening redness to that list. The reason for the urgency is infection inside the eye, which is rare but moves fast, and the treatment for it works better in hours than in days. Say the words recent eye injection when you call, because that phrase changes how quickly you are seen.
If your blood thinner has been paused for any reason, know the signs of the clot it was holding off. Call 911 for weakness or numbness on one side, facial droop, trouble speaking, sudden severe headache, chest pain, or breathlessness with a swollen painful calf. These are not injection complications. They are the reason the pause conversation belongs to your prescriber, and the reason nobody should shorten it by deciding alone.
Common Questions About Blood Thinners and Eye Injections
The doctor who prescribed the blood thinner decides. The eye surgeon should not be the one telling you whether to withdraw the medicine or for how long, because the prescribing physician knows your risk profile much better and is the right person to make that call4. Ask your eye clinic to write down exactly what they are proposing and why, then take that to your prescriber. Two clinics talking to each other settles this faster than you relaying messages between them.
It counts as an antithrombotic, and your eye team will want to know about it, but it sits at the gentler end. In the series of 3,106 injections, 1,254 injections were given to people taking aspirin and no bleeding complications were recorded in that group3. A larger analysis did find higher odds of a bleed needing surgery with antiplatelet drugs, about 1.4 times, and higher again when combined with an anticoagulant6. Mention it. Do not stop it on your own.
On the surface of the eye, quite possibly, and that part is harmless. A small bleed where the needle enters usually clears within a week5. Bleeding inside the eye is the real concern, and it is uncommon. One series of 3,106 injections recorded no such bleeds in the anticoagulated groups3, while a much larger database study found the odds of a bleed needing surgery roughly 1.9 times higher with anticoagulants6. Your team weighs that against what the medicine is protecting.
Tell someone today rather than at your next appointment. Call the clinic that prescribed it, say how many doses you have missed and when, and ask what to do next. Do not simply double up to catch up unless you are told to. Guidance for eye procedures is explicit that anticoagulants should not be discontinued without consulting the provider managing them1. Restarting is usually straightforward, and it is a phone call rather than an emergency for most people.
Because the evidence has a real gap in it, and careful clinicians fill gaps differently. There are not yet clear guidelines on how to manage the newer oral anticoagulants in patients needing eye operations, and a large study has been called for to quantify the risk better7. What is consistent across clinics is the process: the prescriber decides, the eye team documents, and nobody stops anything unilaterally. If the advice you get is vague, ask for it in writing.
Usually not, if it is only red. A flat red patch on the white of the eye, with normal vision and no pain, is blood under the surface membrane. It usually heals within a week5. Blood thinners make it larger and more common. What changes the answer is company: redness that worsens, plus pain, light sensitivity, more floaters, or reduced vision, needs a same day call, because those together can mean infection inside the eye.
More Questions People Ask Their Retina Specialist
Unless your prescriber has told you otherwise, keep to your normal schedule. Changing the timing of a dose is still changing the medicine, and the same rule applies: that decision belongs to the person managing it. Anticoagulants should not be discontinued without consultation with the provider managing them1. If you have been given a written instruction from your heart or stroke clinic, bring it with you and hand it over at check-in.
Say so clearly, because combinations are where the evidence is least reassuring. In the nationwide study, taking an anticoagulant and an antiplatelet together carried the highest odds of a bleed inside the eye needing surgery, about 2.3 times, compared with about 1.9 times for an anticoagulant alone6. That is a reason for closer follow-up and a conversation with your prescriber, not a reason to drop one yourself. People on two are usually on two for a serious reason.
For bleeding, the needle matters more than what is in it, so the answer is broadly the same. Steroid injections carry their own separate issue instead. Eye pressure rises in roughly 30 to 60 of every 100 eyes after an injection of the steroid triamcinolone, while infection inside the eye after an injection runs from about 1 of every 10,000 cases to about 3 of every 1,0008. If you are switching from one type to the other, ask what changes in your monitoring, not what changes in your tablets.
For most people, yes, and that is the whole reason the default is to leave it alone. In people with atrial fibrillation or a mechanical valve, about 20 of every 100 clotting episodes are fatal and about 40 of every 100 cause lasting disability4. That is why the default is to leave a working blood thinner alone unless the prescriber has a specific reason to change it.
Take this list in with you and write the answers down.
- Does anything about my blood thinner change for this injection, and who made that decision?
- Which of my medicines counts as an antithrombotic, and does my aspirin count?
- Who is calling my heart, stroke or clotting doctor, and by when?
- How red should I expect my eye to look afterwards, and for how long?
- Which symptoms mean I call the same day, and what number do I use out of hours?
- Given my medicines, is there anything different you will watch for at my follow-up scans?
- UC San Diego Health anticoagulation guidelines for health care professionals (2024). Peri-Procedural Anticoagulation Guidelines: Ophthalmologic Procedures.
- American Academy of Ophthalmology Clinical Statement (2025). Intravitreal Injections (AAO Clinical Statement, revised and approved February 2025).
- Retina (Mason JO 3rd, Frederick PA, Neimkin MG, White MF Jr, Feist RM, Thomley ML, Albert MA Jr), retrospective case series of 520 consecutive patients (675 eyes) receiving 3,106 anti-VEGF injections (2010). Incidence of hemorrhagic complications after intravitreal bevacizumab (avastin) or ranibizumab (lucentis) injections on systemically anticoagulated patients.
- American Academy of Ophthalmology EyeNet Magazine (Stuart A, quoting Fountain TR and Black EH) (2016). Perioperative Management of Antithrombotics.
- The American Society of Retina Specialists, patient education (2024). Intravitreal Injections (patient information).
- JAMA Network Open (Kim MS, Nam S, Lee J, Woo SJ), nationwide population-based retrospective cohort (94,449 patients) with a nested case-control analysis (8,110 patients) using Korean Health Insurance Review and Assessment Service data, May 2014 to April 2023 (2025). Antithrombotic Medications and Intraocular Hemorrhage Risk in Exudative Age-Related Macular Degeneration.
- American Academy of Ophthalmology EyeNet Magazine (reporting work of Etminan M) (2017). Oral Anticoagulants and Intraocular Hemorrhage.
- Retinal Physician (Fleissig E, Loewenstein A), narrative review (2022). Complications of Intravitreal Injections.